VICORE PHARMA HOLDING AB ADR

VCRENASDAQ

🏆 #2983 by market capEarnings Aug 21US Equity

$12.44▲ $0.55 (+4.45%)

Live

1h—

24h▲ 4.5%

7d▲ 9.2%

14d▼ 5.7%

30d▼ 5.7%

1y—

🏦Market Cap

$3.50B

Small Cap

📈Revenue Growth (YoY)

-41.2%

Declining

📊Gross Margin

360.3%

High

💵FCF Margin

—

⚖️P/S Ratio

923.0x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $12.27 – $12.68
52-Week Range: —
Volume: $2.45B
Avg Volume: $2.12B
Shares Outstanding: 281.5M
Next Earnings: Sep 23, 2026

Fundamentals Snapshot

Annual Revenue: $356,071
Last Q Revenue: $93,509
P/E Ratio: —
P/S Ratio: 923.0x
EPS (TTM): —
Dividend Yield: —

Why Investors Own VCRE

✓High-growth profile — revenue up +3.4% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$356,071▲ +8.2% YoY

Gross Margin (TTM)

39.5%▲ +3.1% YoY

Operating Income (TTM)

$64,449▲ +8.2% YoY

Free Cash Flow (TTM)

$38,100▲ +8.2% YoY

About VICORE PHARMA HOLDING AB ADR

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.

🦦